UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 7, 2002
Shire Pharmaceuticals Group plc
- -------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
England and Wales
- -------------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
0-29630 98-0359573
- ------------------------ -------------------------------
(Commission File Number) (IRS Employer Identification No.)
Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England
- -------------------------------------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code 44 1256 894 000
------------------------
- -------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events
Shire Pharmaceuticals Group plc ("Shire") is a "foreign private issuer" as
defined in the rules of the Securities and Exchange Commission. As a foreign
private issuer, Shire is not subject to the proxy solicitation rules under the
Securities Exchange Act of 1934 (the "Exchange Act") and will not be filing a
proxy statement in respect of its forthcoming annual general shareholder's
meeting pursuant to Regulation 14A under the Exchange Act. Shire's Notice of
Annual Meeting and Form of Proxy are being filed pursuant to this report of Form
8-K.
Item 7. Financial Statements and Exhibits
(c) Exhibits. The following exhibits are filed herewith:
99.1 Notice of Annual General Meeting.
99.2 Form of Proxy.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: May 13, 2002 SHIRE PHARMACEUTICALS GROUP PLC
By: /s/ Angus Russell
-------------------------------------------
Name: Angus Russell
Title: Group Finance Director
EXHIBIT INDEX
Number Description
99.1 Notice of Annual General Meeting.
99.2 Form of Proxy.